Article
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
HIV clinical trials - 1 Jan 2000
Squires Kathleen E, Young Benjamin, DeJesus Edwin, Bellos Nicholas, Murphy Daniel, Sutherland-Phillips Denise H, Zhao Henry H, Patel Lisa G, Ross Lisa L, Wannamaker Paul G, Shaefer Mark S
Abstract excerpt
PURPOSE: The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by simplification to ATV + ABC/3TC in antiretroviral-naïve patients. METHODS: This report includes a noncomparative analysis of all patients in the induction phase of the ARIES study through 36 weeks (clinicaltrials.gov: NCT00440947). This open-label study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.